US EditionQRL Bioscience raises ₹3 crore from GVFL to advance regenerative therapies - Express Pharma
Summary by Express Pharma
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
QRL Bioscience raises ₹3 crore from GVFL to advance regenerative therapies - Express Pharma
QRL Bioscience has raised ₹3 crore in its latest funding round from GVFL, a venture capital firm based in India. The capital will support clinical and preclinical work on the company’s regenerative therapies for diabetic foot ulcers (DFU) and osteoarthritis. Founded by Dr Senthilkumar Natesan, Mr. Sanjoy Bhagat, and Dr Kranti Vora, QRL Bioscience is focused on personalised, cell-based therapies for chronic degenerative diseases. Dr Natesan is a …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
